1. Introduction {#sec1}
===============

There is an urgent need to identify drugs and drug targets which are effective in treating COVID-19. Numerous drug targets have been suggested \[[@bib1]\] and a plethora of drug repurposing efforts are underway \[[@bib2],[@bib3]\]. Transmembrane Serine Protease 2 (TMPRSS2) is a membrane bound serine protease also known as Epitheliasin. TMPRSS2 belongs to the S1A class of serine proteases alongside proteins such as factor Xa and trypsin. Whilst there is evidence that TMPRSS2 autoclaves to generate a secreted protease \[[@bib4]\], its physiological function has not been clearly identified, However, it is known to play a crucial role in facilitating entry of coronavirus particles into cells by cleaving the spike protein \[[@bib5],[@bib6]\]. Coronavirus spike proteins are thought to be cleaved at two sites, termed S1/S2 and S2' \[[@bib7], [@bib8], [@bib9]\]. The proteases furin, trypsin, cathepsin, TMPRSS2, TMPRSS4, TMPRSS11, and human airway trypsin-like protease have all been implicated in these cleavages \[[@bib9], [@bib10], [@bib11], [@bib12], [@bib13]\]. For SARS-CoV, the S2′ cleavage site has a sequence motif (PTKR\|S) that appears suitable for cleavage by trypsin-like proteases such as TMPRSS2 whereas the S1/S2 cleavage site has a sequence motif (SLLR\|S) that appears suitable for cleavage by cathepsin or trypsin-like proteases. Whilst the SARS-CoV-2 S2' cleavage site has a similar sequence motif to SARS-CoV (PSKR\|S) and would thus be suitable for cleavage by trypsin-like proteases, insertions of additional arginine residues at the SARS-CoV-2 S1/S2 cleavage site (RRAR\|S) clearly generate a furin cleavage site \[[@bib14],[@bib15]\]. Interestingly, this difference has been implicated in viral transmissibility of SARS-CoV-2 \[[@bib16]\]. In theory, preventing cleavage at either site should be deleterious to viral invasion.

There is good evidence that TMPRSS2 represents a good drug target for coronaviruses. TMPRSS2-expressing cells are more susceptible to SARS-CoV-2 infection and knockout mouse models show that lack of TMPRSS2 in the airways reduces the severity of lung pathology after SARS-CoV and MERS-CoV infection \[[@bib17]\]. For this reason, it has been suggested as a potential drug target for coronaviruses \[[@bib18],[@bib19]\] such as SARS-CoV-2 \[[@bib20]\]. TMPRSS2 is highly expressed in lung tissue \[[@bib21]\] and it has been suggested that differential expression in males may lead to higher risk in male patients \[[@bib20],[@bib22],[@bib23]\] Peptidic inhibitors of TMPRSS2 have been described \[[@bib12]\] and the covalent TMPRSS2 inhibitor Camostat is being tested in a clinical trial against COVID-19. However, in this study we identify a number of experimental drugs with the potential to target TMPRSS2. MEROPS, the peptide database, lists 219 members of the S1A family in humans \[[@bib24]\]. Many of the members in this family have been studied in detail, yielding numerous high resolution crystal structures, known inhibitors, and licensed drugs \[[@bib25]\]. Importantly, the S1A family has a conserved fold with an arginine binding site that is targeted by the majority of small molecule inhibitors and drugs with its three catalytic residues (aspartate, histidine, and serine) in close proximity to the arginine binding site. In this study we generate homology models of human TMPRSS2 in the apo state as well as in complex with substrate peptide and a number of small molecule experimental drugs.

2. Materials and methods {#sec2}
========================

2.1. Development of a TMPRSS2 homology model {#sec2.1}
--------------------------------------------

TMPRSS2 is in the S1A serine protease family. Sequences for all the human members of the family are available on Github: <https://github.com/djhuggins/TMPRSS2/tree/master/Sequences>.

We aligned the complete sequences with Clustal Omega \[[@bib26]\]. The overall sequence identity between TMPRSS2 and the other S1A family proteases is available on Github: <https://github.com/djhuggins/TMPRSS2/tree/master/Alignments>.

We selected a subset of sequences for alignment based on availability of structural data and similarity between sequences in the active site. We looked in particular at the identity in the active site of the enzymes to inform model and compound selection. We identified 20 residues close to the active site (S1--S1′) as well as a larger set of 34 residues spanning the whole binding site (S4--S3--S2--S1--S1′-S2′-S3′-S4′). These residues are identified in [Fig. 1](#fig1){ref-type="fig"} . The percentage identities between TMPRSS2 and this subset are given in [Table 1](#tbl1){ref-type="table"} :Fig. 1Sequence alignment between the serine protease domains of TMPRSS2 and TMPRSS15. The loop regions that were remodelled are highlighted by green bars. TMPRSS2 residues in the S4--S3--S2--S1--S1′-S2′-S3′-S4′ subsites are colored red. TMPRSS2 residues in the S1--S1′ subsites are further highlighted in bold. The lysine residue between the S2/S3 subsites is highlighted with a blue arrow. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article).Fig. 1Table 1A subset of human S1A serine proteases and the percentage identity with TMPRSS2 of their protease domains, S1--S1′ subsites, and S4--S3--S2--S1--S1′-S2′-S3′-S4′ subsites.Table 1Protein NameUniprot NameTMPRSS2 Protease Domain % IdentityTMPRSS2 S4--S4' % IdentityTMPRSS2 S1--S1' % IdentityPlasminogenPLMN_HUMAN41.0764.7195.00uPAUROK_HUMAN33.7758.8295.00Trypsin-1TRY1_HUMAN38.6058.8290.00Plasma kallikreinKLKB1_HUMAN41.9961.7685.00Coagulation factor VIIFA7_HUMAN38.1661.7685.00HepsinHEPS_HUMAN41.8858.8285.00TMPRSS15TMPRSS15_HUMAN41.3058.8285.00Coagulation factor XIFA11_HUMAN42.1755.8885.00TMPRSS11ETM11E_HUMAN40.2755.8880.00Tryptase gammaTRYG1_HUMAN39.8252.9480.00Coagulation factor IXFA9_HUMAN39.1952.9480.00Coagulation factor XIIFA12_HUMAN36.8950.0080.00Coagulation factor XFA10_HUMAN36.7747.0680.00Chymotrypsin BCTRB2_HUMAN40.9144.1265.00

Importantly, many of the proteases have 80% or higher identity with TMPRSS2 in the S1--S1′ subsites, with plasminogen and urokinase-type plasminogen activator (uPA) having 95% identity. We selected the protein TMPRSS15 to generate a homology model (also known as enteropeptidase). TMPRSS15 provides a good template for building a homology model of TMPRSS2, with a deletion of two residues and an insertion of one residue. It also features a lysine residue in the S2/S3 subsites, which is unique to TMPRSS2 and TMPRSS15. The alignment of the TMPRSS2 and TMPRSS15 protease domains is shown in [Fig. 1](#fig1){ref-type="fig"}.

To build a homology model, the structure of TMPRSS15 was taken from PDB ID [4DGJ](pdb:4DGJ){#intref0020} \[[@bib27]\]. Selenomethionines were changed to methionines and missing side-chains were added using Schrödinger's Preparation Wizard, which was also used to evaluate the orientations of the asparagine, glutamine, and histidine residues, as well as the protonation state of all ionizable residues. All heteroatomic species such as buffer solvents and ions were removed. Water molecules in the arginine binding site were retained. The TMPRSS2 loop sequences EKPLNNPWH, QSFMSY, and VYDNLITPA (see [Fig. 1](#fig1){ref-type="fig"}) were remodelled using Schrodinger's Prime and the whole protein was then energy minimized with the heavy atoms converged to an RMSD of 0.3 Å. The homology model of TMPRS22 is available on Github overlaid with the benzamidine molecule from PDBID [2OQ5](pdb:2OQ5){#intref0025} \[[@bib28]\]: <https://github.com/djhuggins/TMPRSS2/blob/master/HomologyModels/TMPRSS2_HomologyModel_Enteropeptidase4DGJ_BenzamidineOverlay.pdb>.

To assess the quality of the homology model, we performed 100 ns of molecular dynamics using the Desmond package. The system was set up as an orthorhombic box with a minimum distance of 10 Å from the protein to the box edge. Water was modelled with the SPC water model and the OPLS3e forcefield was used for the protein and ligand. 100 ns of simulation was then performed in the NPT ensemble at 300 K and 1.01325 bar. [Fig. 2](#fig2){ref-type="fig"} shows the RMSD of the protein and the ligand during the simulation. Both stabilize within the first 10 ns? The protein remains stable, with an alpha carbon RMSD around 1.7 Å relative to the original structure and always below 2.0 Å. The ligand also remains stable, with an RMSD around 0.9 Å relative to the original structure and always below 2.5 Å.Fig. 2The RMSD of the protein alpha carbons relative to the original structure (blue) and the RMSD of the ligand relative to the original structure (red) across the 100 ns simulation. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article).Fig. 2

We also generated a model of TMPRS22 bound to an eight-residue sequence from the SARS-CoV-2 S2′ cleavage site (PSKR\|SFIE). The structure of the peptide was based on the structure of bovine pancreatic trypsin inhibitor (BPTI) bound to anionic trypsin from PDBID [3FP6](pdb:3FP6){#intref0035} \[[@bib29]\]. We used the backbone residues of BPTI and generated a homology model of the SARS-CoV-2 S2' sequence. The structure of the peptide was then energy minimized. [Fig. 3](#fig3){ref-type="fig"} shows the model, highlighting the eight subsites.Fig. 3Predicted structure of the SARS-CoV-2 S2′ cleavage site sequence PSKRSFIE bound to the homology model of TMPRS22. The TMPRSS2 protein is displayed as green ribbons with atoms in green wire. The peptide is displayed as cyan balls and sticks. Residues within 4 Ångström of the S1--S1′ sites are displayed as red space filling. Residues within 4 Ångström of the S4--S3--S2--S1--S1′-S2′-S3′-S4′ sites are displayed as orange sticks. The eight subsites and residue Lys392 are denoted. The homology model of TMPRS22 overlaid with the SARS-CoV-2 S2′ cleavage site PSKRSFIE 8-mer is available on Github: <https://github.com/djhuggins/TMPRSS2/blob/master/HomologyModels/TMPRSS2_HomologyModelFrom4DGJ_SubstrateOverlay.pdb>. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article).Fig. 3

2.2. Identification of small molecule drugs targeting S1A serine proteases {#sec2.2}
--------------------------------------------------------------------------

In order to identify potential drugs that might inhibit TMPRSS2, we exploited structural modelling data from related serine proteases. We used the MEROPS database to identify all proteins in the S1A family \[[@bib24]\]. We then used Drugbank \[[@bib30]\] to identify 36 drug targets in the S1A family for which approved, investigational or experimental drugs are available. A list of the target names, UniProt identifiers, and Drugbank ID of these proteins is available on Github: <https://github.com/djhuggins/TMPRSS2/blob/master/DrugBankData/S1ASerineProtease_DrugBank_TargetIDs.csv>.

A list of all the 376 Drugbank drugs targeting S1A serine proteases is also available on Github: <https://github.com/djhuggins/TMPRSS2/blob/master/DrugBankData/S1ASerineProtease_DrugBank_DrugIDs.csv>.

Included with this is the list of DrugBank molecules for each target and a list of the Protein Databank PDB identifiers \[[@bib31]\] of these drugs bound to the targets. Of these 36 targets, the 32 targets for which PDB structural data is available are reported in [Table 2](#tbl2){ref-type="table"} .Table 2Human protein targets in the S1A serine protease family with structural data for approved, investigational or experimental drugs.Table 2Protein NameUniProt IDUniProt Gene NameDrugBank Target IDApolipoprotein(a)[P08519](uniprotkb:P08519){#intref0145}APOA_HUMAN1283Cathepsin G[P08311](uniprotkb:P08311){#intref0150}CATG_HUMAN1010Chymase[P23946](uniprotkb:P23946){#intref0155}CMA1_HUMAN1038Coagulation factor IX[P00740](uniprotkb:P00740){#intref0160}FA9_HUMAN364Coagulation factor VII[P08709](uniprotkb:P08709){#intref0165}FA7_HUMAN333Coagulation factor X[P00742](uniprotkb:P00742){#intref0170}FA10_HUMAN216Coagulation factor XI[P03951](uniprotkb:P03951){#intref0175}FA11_HUMAN1021Coagulation factor XII[P00748](uniprotkb:P00748){#intref0180}FA12_HUMAN4672Complement C1r subcomponent[P00736](uniprotkb:P00736){#intref0185}C1R_HUMAN2093Complement C1s subcomponent[P09871](uniprotkb:P09871){#intref0190}C1S_HUMAN1529Complement factor B[P00751](uniprotkb:P00751){#intref0195}CFAB_HUMAN1701Complement factor D[P00746](uniprotkb:P00746){#intref0200}CFAD_HUMAN1840Complement factor I[P05156](uniprotkb:P05156){#intref0205}CFAI_HUMAN8979Haptoglobin[P00738](uniprotkb:P00738){#intref0210}HPT_HUMAN10,260Hepatocyte growth factor[P14210](uniprotkb:P14210){#intref0215}HGF_HUMAN1121Kallikrein-6[Q92876](uniprotkb:Q92876){#intref0220}KLK6_HUMAN1586Kallikrein-7[P49862](uniprotkb:P49862){#intref0225}KLK7_HUMAN4150Myeloblastin[P24158](uniprotkb:P24158){#intref0230}PRTN3_HUMAN954Neutrophil elastase[P08246](uniprotkb:P08246){#intref0235}ELNE_HUMAN394Plasma kallikrein[P03952](uniprotkb:P03952){#intref0240}KLKB1_HUMAN2440Plasminogen[P00747](uniprotkb:P00747){#intref0245}PLMN_HUMAN211Prostasin[Q16651](uniprotkb:Q16651){#intref0250}PRSS8_HUMAN3746Prostate-specific antigen[P07288](uniprotkb:P07288){#intref0255}KLK3_HUMAN8908Prothrombin[P00734](uniprotkb:P00734){#intref0260}THRB_HUMAN48Serine protease hepsin[P05981](uniprotkb:P05981){#intref0265}HEPS_HUMAN2128Tissue-type plasminogen activator[P00750](uniprotkb:P00750){#intref0270}TPA_HUMAN1088Trypsin-1[P07477](uniprotkb:P07477){#intref0275}TRY1_HUMAN1739Trypsin-3[P35030](uniprotkb:P35030){#intref0280}TRY3_HUMAN1583uPA[P00749](uniprotkb:P00749){#intref0285}UROK_HUMAN895Vitamin K-dependent protein C[P04070](uniprotkb:P04070){#intref0290}PROC_HUMAN380Vitamin K-dependent protein Z[P22891](uniprotkb:P22891){#intref0295}PROZ_HUMAN547

We identified 250 approved, investigational or experimental drugs targeting S1A proteases for which structural data is available. These drugs correspond to 479 PDB structures. We downloaded the structural data for these drugs in complex with their targets and aligned them in the same reference frame. The aligned structures are available on Github: <https://github.com/djhuggins/TMPRSS2/tree/master/AlignedPDBs>.

We overlaid the homology model of TMPRSS2 with the PDB structures containing the approved, investigational or experimental small-molecule drugs for S1A serine proteases. We selected a subset of these molecules based on fit within the homology model of TMPRSS2. We then used Embrace minimization with GBSA solvation to test whether all molecules fit with the homology model of TMPRSS2 \[[@bib32]\]. The use of minimization ensures that the resulting complexes to do contain any clashes or bad contacts.

3. Results {#sec3}
==========

Based on the homology model described above, the S2--S3 subsites of TMPRSS2 appear to be different than that of related proteases due to the presence of a charge residue Lys392 (see [Fig. 3](#fig3){ref-type="fig"}). Whilst this suggests that many existing serine protease inhibitors which fill these subsites will not bind to TMPRSS2, it presents an opportunity to develop selective inhibitors in the future to exploit TMPRSS2 selectively in therapeutic settings. [Fig. 4](#fig4){ref-type="fig"} presents the predicted TMPRSS2 binding modes for a set of non-covalent S1A serine protease experimental drugs overlaid with the experimental crystal structures of the drugs bound to their known target. These drugs target the S1--S1′ subsites where identity between the S1A serine proteases is very high (see [Table 2](#tbl2){ref-type="table"}).Fig. 4Putative model of TMPRSS2 bound to the experimental drugs from (a) Trypsin in PDBID [1GHV](pdb:1GHV){#intref0105} \[[@bib33]\], (b) uPA in PDBID [1SQA](pdb:1SQA){#intref0110} \[[@bib34]\], (c) uPA in PDBID [2VIV](pdb:2VIV){#intref0115} \[[@bib35]\], (d) factor VII in PDBID [2FLR](pdb:2FLR){#intref0120} \[[@bib36]\], (e) uPA in PDBID [1EJN](pdb:1EJN){#intref0125} \[[@bib37]\], (f) uPA in PDBID [1OWH](pdb:1OWH){#intref0130} \[[@bib38]\], (g) hepsin in PDBID [1O5E](pdb:1O5E){#intref0135} \[[@bib39]\], and (h) uPA in PDBID [1GJC](pdb:1GJC){#intref0140} \[[@bib40]\]. The TMPRSS2 protein is displayed as green ribbons with atoms in green wire and the predicted binding modes of the experimental drugs in TMPRSS2 are shown in green balls and sticks. The experimental protein structures are displayed as different colored ribbons with wire atoms and the binding modes of the experimental drugs are shown as balls and sticks. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 4

The predicted complexes and a file with their Embrace MMGBSA scores are available on Github: <https://github.com/djhuggins/TMPRSS2/tree/master/Embrace>.

The S1--S1′ subsites of TMPRSS2 has a high similarity to the known targets of all these drugs (see [Table 1](#tbl1){ref-type="table"}). [Table 3](#tbl3){ref-type="table"} reports further details for the drugs in [Fig. 4](#fig4){ref-type="fig"}.Table 3A set of experimental drugs targeting S1A serine proteases that may inhibit TMPRSS2 and are modelled in [Fig. 3](#fig3){ref-type="fig"}.Table 3Drugbank IDCrystallized ProteinPDB IDNotesDB04442Trypsin1GHZDB03082uPA1SQAAbbott compoundDB08697uPA2VIVAstex compoundDB07247Factor VII2FLRDB03782uPA1EJNDB02398uPA1OWHDB03865Hepsin1O5ETrypsin/thrombin/uPA/hepsin inhibitorDB01725uPA1GJCTrypsin/thrombin/uPA inhibitor

All the small molecule drugs with an experimental crystal structure are reported on Github: <https://github.com/djhuggins/TMPRSS2/blob/master/DrugBankData/S1ASerineProtease_DrugBank_DrugIDs_WithPDBData.csv>.

We predict that a number of these may also inhibit TMPRSS2 and could prove effective as treatments for COVID-19. If hitting numerous host proteases is important then simple molecules such as DB04442 may prove more effective.

4. Discussion {#sec4}
=============

A number of drug targets have been suggested for coronaviruses \[[@bib41]\] such as SARS-CoV-2. A recent study highlights that three covalent inhibitors of the drug target TMPRSS2 blocked SARS-CoV-2 infection of human lung cells, with nafamostat \[[@bib42]\] showing better than camostat or gabexate \[[@bib43]\]. Non-viral drug targets such as TMPRSS2 have the advantage that the virus cannot develop resistance mutations that reduce the affinity of the drug for the target. Mutations that allow the virus to utilize alternative host proteases are possible, but the corresponding change in pathogenesis leads to a higher likelihood of being deleterious to viral fitness. As a drug target TMPRSS2 has the additional advantage that the drug discovery community has significant experience in developing drugs targeting serine proteases. For instance, many diverse and high affinity inhibitors have been synthesized for widely studied S1A serine protease targets such as Thrombin and Factor Xa \[[@bib44]\].

A number of host proteases have been implicated in cleavage of the coronavirus including furin, trypsin, cathepsins, TMPRSS2, TMPRSS4, and human airway trypsin-like protease \[[@bib45]\]. Given the furin cleavage in SARS-CoV-2 it seems likely that furin-targeted drugs would prove useful in treating the virus \[[@bib14]\]. Whilst there are no drugs that specifically target furin, it is possible that Camostat targets furin in addition to S1A proteases given a mechanism of action where it covalently binds to the arginine binding site. However, at this stage there is significantly more evidence that targeting TMPRSS2 will effectively treat SARS-CoV-2. The known TMPRSS2 inhibitor Camostat is being assessed in a clinical trial against COVID-19 and other inhibitors, such as Namafostat, look to be effective in cell-based studies. However, it seems highly likely that these simple covalent binders may inhibit other S1A serine proteases and this may lead to unwanted side effects for these drugs. TMPRSS2 knockout mice develop normally with no observable phenotype suggesting that it may be safely targeted \[[@bib46]\]. To maximize safety, it would be very useful to identify exactly which proteases are key to cleaving the SARS-CoV-2 spike protein. Recent work suggests that TMPRSS2 and TMPRSS4 may both be important \[[@bib47]\]. This work identifies a number of experimental drugs for serine proteases that may effectively inhibit TMPRSS2 based on homology and Embrace binding free energy calculations. Three are shown in [Table 4](#tbl4){ref-type="table"} .Table 4Three of the TMPRSS2 Embrace top scoring serine protease inhibitors.Table 4Drugbank IDStructureProtein TargetDB03782![](fx2_lrg.gif)Urokinase-type plasminogen activatorDB03213![](fx3_lrg.gif)Trypsin-1DB04107![](fx4_lrg.gif)Trypsin-1

All three molecules in [Table 4](#tbl4){ref-type="table"} contain a positively charged warhead similarly to nafamostat, camostat, and gabexate (guanidine in the case of to DB03782, nafamostat, camostat, and gabexate versus amidine in the case of DB03213 and DB04107). The vast majority of the 376 serine protease inhibitors contain such a warhead.

In this study we have highlighted a large number of S1A serine protease inhibitors with experimental drug status that may inhibit TMPRSS2. Assays have previously been reported that would allow these molecules to be tested against TMPRSS2(12) \[[@bib48]\] and one or more of these may have the appropriate PK properties to attain sufficiently high concentrations in the lung and effectively treat COVID-19.
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